Brief: SYNLAB And OncoDNA To Provide Comprehensive Biomarker Testing For Cancer Therapy Selection

Synlab AG

29/03/2022 07:07

March 29 (Reuters) - SYNLAB AG  SYAB.DE :
    * PARTNERS WITH ONCODNA TO PROVIDE COMPREHENSIVE BIOMARKER
TESTING
FOR CANCER THERAPY SELECTION IN GERMANY
    * WITH PARTNERSHIP, SYNLAB FURTHER EXPANDS ITS SUBSTANTIVE
ONCOLOGY SERVICES AND CONTINUES ITS FOCUS ON PERSONALISED
DIAGNOSTICS AND PRECISION MEDICINE
    * COMPREHENSIVE TEST WILL HELP ONCOLOGISTS DECIDE ON MOST
EFFECTIVE TREATMENT FOR CANCER PATIENTS
    * WILL PROVIDE HIGH-QUALITY, PAN-CANCER ONCODEEP(R)
BIOMARKER TEST
TO OPTIMIZE PREDICTION OF PATIENT RESPONSES TO A WIDE RANGE OF
APPROVED AND EXPERIMENTAL THERAPIES

Source text for Eikon:  ID:nEQ9KBJ7Ka 
Further company coverage:  SYAB.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))